<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00359164</url>
  </required_header>
  <id_info>
    <org_study_id>C06-0202</org_study_id>
    <secondary_id>V06-0157</secondary_id>
    <nct_id>NCT00359164</nct_id>
  </id_info>
  <brief_title>Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.</brief_title>
  <official_title>A Randomized, Controlled, Double-Masked, Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab (Avastin), in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <brief_summary>
    <textblock>
      To determine if Visudyne photodynamic therapy (low or very low fluence rate) combined with
      intravitreal injections of bevacizumab (Avastin) compared with bevacizumab alone will, with
      similar safety and efficacy, delay time to retreatment with bevacizumab after the initial
      treatment, in subjects with new wet AMD Hypothesis: PDT in combination with Avastin at either
      the low or very low fluence rate will delay time to retreatment and reduce the average number
      of treatments required, compared to Avastin alone, but will have a similar safety and
      efficacy profile.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if Visudyne therapy (low or very low fluence rate) combined with bevacizumab compared with bevacizumab alone will, with similar safety and efficacy, delay time to retreatment with bevacizumab</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if Visudyne therapy (low or very low fluence rate) combined with bevacizumab compared with bevacizumab alone will, with similar safety and efficacy, reduce the average number of bevacizumab treatments</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab with verteporfin at Low Fluence Photodynamic Therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab with verteporfin at Very Low Photodynamic Therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Bevacizumab with verteporfin with Sham Photodynamic Therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab</intervention_name>
    <description>Bevacizumab 1.25 mg with verteporfin at Low Fluence (300 mW/cm2 delivered for 83 seconds [light dose of 25 J/cm2]) Photodynamic Therapy.
Treatment at Baseline visit, followed by an &quot;as needed&quot; basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Verteporfin = Visudyne</other_name>
    <other_name>Bevacizumab = Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab</intervention_name>
    <description>Bevacizumab 1.25 mg with verteporfin at Low Fluence (150 mW/cm2 delivered for 83 seconds [light dose of 12.5 J/cm2]) Photodynamic Therapy.
Treatment at Baseline visit, followed by an &quot;as needed&quot; basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Verteporfin = Visudyne</other_name>
    <other_name>Bevacizumab = Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verteporfin Photodynamic Therapy (SHAM) and bevacizumab</intervention_name>
    <description>Bevacizumab with SHAM (150 mW/cm2 delivered for 83 seconds [light dose of 12.5 J/cm2]) Photodynamic Therapy.
Treatment at Baseline visit, followed by an &quot;as needed&quot; basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Verteporfin = Visudyne</other_name>
    <other_name>Bevacizumab = Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        new wet AMD

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Potter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver General Hospital Eye Care Centre (UBC)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3N9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2006</study_first_submitted>
  <study_first_submitted_qc>July 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2006</study_first_posted>
  <last_update_submitted>August 12, 2008</last_update_submitted>
  <last_update_submitted_qc>August 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Michael Potter</name_title>
    <organization>University of British Columbia</organization>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>Avastin</keyword>
  <keyword>Visudyne</keyword>
  <keyword>Medical condition being studied AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

